Soluble form of receptor for advanced glycation end-products (sRAGE): Do sRAGE ligands or anti-sRAGE auto-antibodies interfere with sRAGE quantification?

Annals of Clinical Biochemistry

Volumn 51, Issue 2, 2014, Pages 248-257

  Lorenzi, Rodrigo ^a   Grossin, Nicolas ^a   Lambert, Marc ^a   Daroux, Maité ^a,b   Adjoutah, Zoubir ^a   Flahaut, Christophe ^c   Jacolot, Philippe ^d   Tessier, Frédéric J ^d   Lefranc, Didier ^a   Desremaux, Pierre ^a   Dubucquoi, Sylvain ^a   Boulanger, Eric ^a  

^a UNIV LILLE   (France)

^b Department of Nephrology Duchenne Hospital   (France)

^c UNIVERSITÉ D'ARTOIS   (France)

^d INSTITUT POLYTECHNIQUE LASALLE BEAUVAIS   (France)

Author keywords

clinical studies; immunoassay; laboratory methods; Quality assurance control

Indexed keywords

CLINICAL STUDIES; IMMUNOASSAY; LABORATORY METHODS; QUALITY ASSURANCE & CONTROL;

ADULT; AGED; AGED, 80 AND OVER; ARTIFACTS; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIGANDS; MALE; MIDDLE AGED; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IMMUNOLOGIC; RENAL DIALYSIS; SOLUBILITY;

EID: 84898678975     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213493402     Document Type: Article

References (56)

1. Scholze J,Alegria E,Ferri C, et al.Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in germany, spain and italy; a prevalence-based model.BMC Public Health. 2010;10:529-529.
2. Williams JP,Meyers JA.Immune-mediated inflammatory disorders (i.M.I.D.S): the economic and clinical costs.Am J Manag Care. 2002;8:S664-S681.
3. Obesity: preventing and managing the global epidemic: report of a who consultation. Geneva: World Health Organization; 2000:.
4. Diabetes. Geneva: World Health Organization; 2006:.
5. Cardiovascular diseases. Geneva: World Health Organization; 2007:.
6. Dallmeier D,Larson M,Vasan R, et al.Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the framingham heart study.Diabetol Metabol Syndr. 2012;4:1-7.
7. Brownlee IA,Moore C,Chatfield M, et al.Markers of cardiovascular risk are not changed by increased whole-grain intake: the wholeheart study, a randomised, controlled dietary intervention.Br J Nutr. 2010;104:125-134.
8. Schmidt AM,Vianna M,Gerlach M, et al.Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface.J Biol Chem. 1992;267:14987-14997.
9. Yeh CH,Sturgis L,Haidacher J, et al.Requirement for p38 and p44/p42 mitogen-activated protein kinases in rage-mediated nuclear factor-kappab transcriptional activation and cytokine secretion.Diabetes. 2001;50:1495-1504.
10. Bierhaus A,Humpert PM,Nawroth PP.Nf-kappab as a molecular link between psychosocial stress and organ dysfunction.Pediatr Nephrol. 2004;19:1189-1191.
11. Lv B,Wang H,Tang Y, et al.High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of nf-kappab and egr-1.Thromb Haemost. 2009;102:352-359.
12. Boulanger E,Wautier MP,Wautier JL, et al.Ages bind to mesothelial cells via rage and stimulate vcam-1 expression.Kidney Int. 2002;61:148-156.
13. Boulanger E,Grossin N,Wautier MP, et al.Mesothelial rage activation by ages enhances vegf release and potentiates capillary tube formation.Kidney Int. 2007;71:126-133.
14. Leclerc E,Fritz G,Vetter SW, et al.Binding of s100 proteins to rage: an update.Biochim Biophys Acta. 2009;1793:993-1007.
15. Kislinger T,Fu C,Huber B, et al.N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.J Biol Chem. 1999;274:31740-31749.
16. Ramasamy R,Yan SF,Schmidt AM.The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.Vascul Pharmacol. 2012;57:160-167.
17. Sukkar MB,Ullah MA,Gan WJ, et al.Rage: a new frontier in chronic airways disease.Br J Pharmacol. 2012;167:1161-1176.
18. Grossin N,Wautier MP,Meas T, et al.Severity of diabetic microvascular complications is associated with a low soluble rage level.Diabetes Metab. 2008;34:392-395.
19. Kalousova M,Hodkova M,Kazderova M, et al.Soluble receptor for advanced glycation end products in patients with decreased renal function.Am J Kidney Dis. 2006;47:406-411.
20. Nakamura T,Sato E,Fujiwara N, et al.Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.Metabolism. 2009;58:1624-1628.
21. Falcone C,Emanuele E,D'Angelo A, et al.Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.Arterioscler Thromb Vasc Biol. 2005;25:1032-1037.
22. Basta G,Sironi AM,Lazzerini G, et al.Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and s100a12 protein.J Clin Endocrinol Metab. 2006;91:4628-4634.
23. Tan KC,Shiu SW,Chow WS, et al.Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.Diabetologia. 2006;49:2756-2762.
24. Nakamura K,Yamagishi S,Adachi H, et al.Elevation of soluble form of receptor for advanced glycation end products (srage) in diabetic subjects with coronary artery disease.Diabetes Metab Res Rev. 2007;23:368-371.
25. Mulder DJ,van Haelst PL,Gross S, et al.Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products.Atherosclerosis. 2008;197:217-223.
26. Challier M,Jacqueminet S,Benabdesselam O, et al.Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes.Clin Chem. 2005;51:1749-1750.
27. Mruthinti S,Buccafusco JJ,Hill WD, et al.Autoimmunity in alzheimer's disease: increased levels of circulating iggs binding abeta and rage peptides.Neurobiol Aging. 2004;25:1023-1032.
28. Pullerits R,Bokarewa M,Dahlberg L, et al.Synovial fluid expression of autoantibodies specific for rage relates to less erosive course of rheumatoid arthritis.Rheumatology (Oxford). 2007;46:1367-1371.
29. Ikeda K,Higashi T,Sano H, et al.N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the maillard reaction.Biochemistry. 1996;35:8075-8083.
30. Habeeb AF.Determination of free amino groups in proteins by trinitrobenzenesulfonic acid.Anal Biochem. 1966;14:328-336.
31. Xie J,Reverdatto S,Frolov A, et al.Structural basis for pattern recognition by the receptor for advanced glycation end products (rage).J Biol Chem. 2008;283:27255-27269.
32. Daroux M,Prevost G,Maillard-Lefebvre H, et al.Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies.Diabetes Metab. 2010;36:1-10.
33. Niquet-Léridon C,Tessier FJ.Quantification of ne{open}-carboxymethyl-lysine in selected chocolate-flavoured drink mixes using high-performance liquid chromatography-linear ion trap tandem mass spectrometry.Food Chem. 2011;126:655-663.
34. He M,Kubo H,Morimoto K, et al.Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells.EMBO Rep. 2011;12:358-364.
35. Yamamoto Y,Harashima A,Saito H, et al.Septic shock is associated with receptor for advanced glycation end products ligation of lps.J Immunol. 2011;186:3248-3257.
36. Koch M,Chitayat S,Dattilo BM, et al.Structural basis for ligand recognition and activation of rage.Structure. 2010;18:1342-1352.
37. Hori O,Brett J,Slattery T, et al.The receptor for advanced glycation end products (rage) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.J Biol Chem. 1995;270:25752-25761.
38. Leclerc E,Fritz G,Weibel M, et al.S100b and s100a6 differentially modulate cell survival by interacting with distinct rage (receptor for advanced glycation end products) immunoglobulin domains.J Biol Chem. 2007;282:31317-31331.
39. Pullerits R,Bokarewa M,Dahlberg L, et al.Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.Arthritis Res Ther. 2005;7:R817-R824.
40. Bibl M,Esselmann H,Otto M, et al.Cerebrospinal fluid amyloid beta peptide patterns in alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.Electrophoresis. 2004;25:2912-2918.
41. Miller DL,Currie JR,Mehta PD, et al.Humoral immune response to fibrillar beta-amyloid peptide.Biochemistry. 2003;42:11682-11692.
42. Craig AL,Blaydes JP,Burch LR, et al.Dephosphorylation of p53 at ser20 after cellular exposure to low levels of non-ionizing radiation.Oncogene. 1999;18:6305-6312.
43. Cabral AR,Cabiedes J,Alarcon-Segovia D.Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus.Lupus. 2004;13:182-187.
44. Brown LF,Fraser CG.Assay validation and biological variation of serum receptor for advanced glycation end-products.Ann Clin Biochem. 2008;45:518-519.
45. Wittwer C,Lehner J,Fersching D, et al.Methodological and preanalytical evaluation of a rage immunoassay.Anticancer Res. 2012;32:2075-2078.
46. Mruthinti S,Hill WD,Swamy-Mruthinti S, et al.Relationship between the induction of rage cell-surface antigen and the expression of amyloid binding sites.J Mol Neurosci. 2003;20:223-232.
47. Forbes JM,Thorpe SR,Thallas-Bonke V, et al.Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.J Am Soc Nephrol. 2005;16:2363-2372.
48. Humpert PM,Djuric Z,Kopf S, et al.Soluble rage but not endogenous secretory rage is associated with albuminuria in patients with type 2 diabetes.Cardiovasc Diabetol. 2007;6:9-9.
49. Colhoun HM,Betteridge DJ,Durrington P, et al.Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the cards trial.Diabetes. 2011;60:2379-2385.
50. Biswas SK,Mudi SR,Mollah FH, et al.Serum soluble receptor for advanced glycation end products (srage) is independently associated with cigarette smoking in non-diabetic healthy subjects.Diab Vasc Dis Res. 2013;10:380-382.
51. Hudson BI,Moon YP,Kalea AZ, et al.Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan study (nomas).Atherosclerosis. 2011;216:192-198.
52. Norata GD,Garlaschelli K,Grigore L, et al.Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population.Nutr Metab Cardiovasc Dis. 2009;19:129-134.
53. Zakiyanov O,Kalousova M,Kriha V, et al.Serum s100a12 (en-rage) levels in patients with decreased renal function and subclinical chronic inflammatory disease.Kidney Blood Press Res. 2011;34:457-464.
54. Geroldi D,Falcone C,Minoretti P, et al.High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans.J Am Geriatr Soc. 2006;54:1149-1150.
55. Gaens KH,Ferreira I,van der Kallen CJ, et al.Association of polymorphism in the receptor for advanced glycation end products (rage) gene with circulating rage levels.J Clin Endocrinol Metab. 2009;94:5174-5180.
56. Raucci A,Cugusi S,Antonelli A, et al.A soluble form of the receptor for advanced glycation endproducts (rage) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (adam10).FASEB J. 2008;22:3716-3727.